MLYS · Mineralys Therapeutics, Inc.
Market Cap
$2.49B
Shares
88.41M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Jon Congleton | President and Chief Executive Officer | $5,544,727 |
| David Rodman | Chief Medical Officer | $2,204,704 |
| Adam Levy | Chief Financial Officer and Secretary | $2,203,096 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Jon Congleton | President and Chief Executive Officer | $5,420,868 |
| David Rodman | Chief Medical Officer | $2,877,749 |
| Adam Levy | Chief Financial Officer and Secretary | $2,849,200 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Jon Congleton | President and Chief Executive Officer | $5,342,057 |
| David Rodman | Chief Medical Officer | $2,334,207 |
| Adam Levy | Chief Financial Officer and Secretary | $2,176,181 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Jon Congleton | Chief Executive Officer | $1,740,185 |
| David Rodman | Chief Medical Officer | $1,106,507 |
| Adam Levy | Chief Financial Officer and Secretary | $1,016,588 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| James J. Ferguson III, M.D. | Chief Medical Officer | Appointed | 2026-08-11 |
Key facts
CIK
1933414
CUSIP
603170101
13F (30d)
170 filings
169 filers
Visit website
Investor relations